ALZN
Alzamend Neuro, Inc.
Price Chart
Latest Quote
$1.21
-0.01 (-0.82%)
Current Price
| Previous Close | $1.22 |
| Open | $1.18 |
| Day High | $1.24 |
| Day Low | $1.16 |
| Volume | 29,157 |
Stock Information
| Shares Outstanding | 3.80M |
| Cash Equivalents | $2.71M |
| Net Income | $-7.54M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.60M |
| EPS (TTM) | $-3.67 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.89M |
| Income | $-7.54M |
| Book/sh | $0.57 |
| Cash/sh | $0.71 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 1.46 |
| Current Ratio | 1.99 |
Returns & Margins
| ROA | -107.01% |
| ROE | -249.97% |
Ownership
| Insider Ownership | 0.53% |
| Institutional Ownership | 3.04% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.47 |
| P/B | 2.11 |
Analyst Data
| Recommendation | none |
| Target Price | $25.00 |
Technical Indicators
| SMA20 | $1.21 |
| SMA50 | $1.16 |
| SMA200 | $1.76 |
| RSI | 51.35 |
| ATR | 0.1076 |
| Shares Float | 3.79M |
| Short Float | 4.16% |
| Short Ratio | 0.84 |
| Volatility | 0.14 |
| Rel Volume | 0.09 |
Performance History
| Week | +2.54% |
| Month | -5.47% |
| Quarter | +21.00% |
| 6 Months | -46.70% |
| YTD | -36.32% |
| Year | -65.72% |
| 3 Years | -99.82% |
| 5 Years | -99.99% |
| 10 Years | -99.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $1.21 | 29,200 |
| 2026-07-16 | $1.22 | 146,400 |
| 2026-07-15 | $1.23 | 35,400 |
| 2026-07-14 | $1.21 | 71,600 |
| 2026-07-13 | $1.16 | 48,200 |
| 2026-07-10 | $1.18 | 96,500 |
| 2026-07-09 | $1.16 | 38,000 |
| 2026-07-08 | $1.15 | 73,000 |
| 2026-07-07 | $1.14 | 87,400 |
| 2026-07-06 | $1.16 | 71,200 |
| 2026-07-02 | $1.16 | 374,300 |
| 2026-07-01 | $1.12 | 2,335,700 |
| 2026-06-30 | $1.20 | 2,347,300 |
| 2026-06-29 | $1.16 | 58,600 |
| 2026-06-26 | $1.20 | 68,900 |
| 2026-06-25 | $1.29 | 205,400 |
| 2026-06-24 | $1.37 | 39,900 |
| 2026-06-23 | $1.37 | 360,300 |
| 2026-06-22 | $1.22 | 115,400 |
| 2026-06-18 | $1.22 | 45,000 |
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
đ° Latest News
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-01-26T14:40:01Z
EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?
Zacks âĸ 2025-11-20T12:50:00Z
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants
Benzinga âĸ 2025-11-19T12:30:15Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $18,029 | $10,101 | $7,701 | $46,524 |
| Total Expenses | $4,496,824 | $9,937,645 | $14,870,466 | $12,319,535 |
| Net Non Operating Interest Income Expense | $-18,029 | $-10,101 | $-7,701 | $-46,524 |
| Interest Expense Non Operating | $18,029 | $10,101 | $7,701 | $46,524 |
| Operating Expense | $4,496,824 | $9,937,645 | $14,870,466 | $12,319,535 |
| Selling And Marketing Expense | $347,295 | $247,334 | $742,601 | $17,654 |
| General And Administrative Expense | $2,734,601 | $3,235,204 | $6,682,008 | $7,100,567 |
| Other Income Expense | - | - | - | $4,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-4,514,853 | $-9,947,746 | $-14,878,167 | $-12,362,059 |
| Net Interest Income | $-18,029 | $-10,101 | $-7,701 | $-46,524 |
| Normalized Income | $-4,514,853 | $-9,947,746 | $-14,878,167 | $-12,366,059 |
| Net Income From Continuing And Discontinued Operation | $-4,514,853 | $-9,947,746 | $-14,878,167 | $-12,362,059 |
| Total Operating Income As Reported | $-4,496,824 | $-9,937,645 | $-14,870,466 | $-12,319,535 |
| Net Income Common Stockholders | $-5,105,084 | $-9,947,746 | $-14,878,167 | $-12,362,059 |
| Net Income | $-4,514,853 | $-9,947,746 | $-14,878,167 | $-12,362,059 |
| Net Income Including Noncontrolling Interests | $-4,514,853 | $-9,947,746 | $-14,878,167 | $-12,362,059 |
| Net Income Continuous Operations | $-4,514,853 | $-9,947,746 | $-14,878,167 | $-12,362,059 |
| Pretax Income | $-4,514,853 | $-9,947,746 | $-14,878,167 | $-12,362,059 |
| Operating Income | $-4,496,824 | $-9,937,645 | $-14,870,466 | $-12,319,535 |
| Special Income Charges | - | - | $0 | $4,000 |
| Interest Income | - | - | - | $0 |
| Interest Income Non Operating | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-11.32 | $-132.33 | $-228.90 | $-189.00 |
| Basic EPS | $-11.32 | $-132.33 | $-228.90 | $-189.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-4,446,084 | $-9,886,905 | $-14,847,400 | $-12,315,986 |
| Reconciled Depreciation | $50,740 | $50,740 | $23,066 | $3,549 |
| EBITDA (Bullshit earnings) | $-4,446,084 | $-9,886,905 | $-14,847,400 | $-12,311,986 |
| EBIT | $-4,496,824 | $-9,937,645 | $-14,870,466 | $-12,315,535 |
| Diluted Average Shares | $450,799 | $75,174 | $65,012 | $65,996 |
| Basic Average Shares | $450,799 | $75,174 | $65,012 | $65,996 |
| Diluted NI Availto Com Stockholders | $-5,105,084 | $-9,947,746 | $-14,878,167 | $-12,362,059 |
| Preferred Stock Dividends | $590,231 | - | - | - |
| Research And Development | $1,414,928 | $6,455,107 | $7,445,857 | $5,201,314 |
| Selling General And Administration | $3,081,896 | $3,482,538 | $7,424,609 | $7,118,221 |
| Other Gand A | $964,624 | $1,117,360 | $1,276,507 | $1,225,733 |
| Insurance And Claims | $259,382 | $381,737 | $587,427 | $714,329 |
| Salaries And Wages | $1,510,595 | $1,736,107 | $4,818,074 | $5,160,505 |
| Total Unusual Items | - | - | $0 | $4,000 |
| Total Unusual Items Excluding Goodwill | - | - | $0 | $4,000 |
| Other Special Charges | - | - | - | $-4,000 |
Fetched: 2026-07-10
Balance Sheet (Annual)
| Metric | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,968,222 | $-2,594,185 | $3,045,503 | $13,351,511 |
| Total Assets | $4,602,983 | $631,588 | $5,915,625 | $14,516,443 |
| Total Non Current Assets | $425,606 | $176,346 | $79,843 | $102,909 |
| Current Assets | $4,177,377 | $455,242 | $5,835,782 | $14,413,534 |
| Prepaid Assets | $228,719 | $79,194 | $694,923 | $349,723 |
| Cash Cash Equivalents And Short Term Investments | $3,948,658 | $376,048 | $5,140,859 | $14,063,811 |
| Cash And Cash Equivalents | $3,948,658 | $376,048 | $5,140,859 | $14,063,811 |
| Cash Financial | $3,948,658 | $376,048 | $5,140,859 | $14,063,811 |
| Receivables | - | - | - | $0 |
| Current Deferred Assets | - | - | - | - |
| Other Receivables | - | - | - | - |
| Accrued Interest Receivable | - | - | - | - |
| Notes Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | - | $300,714 | - | - |
| Current Debt And Capital Lease Obligation | - | $300,714 | - | - |
| Current Debt | - | $300,714 | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $634,761 | $3,225,773 | $2,870,122 | $1,164,932 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $634,761 | $3,225,773 | $2,870,122 | $1,164,932 |
| Current Notes Payable | $0 | $300,714 | $0 | - |
| Payables And Accrued Expenses | $634,761 | $2,925,059 | $2,870,122 | $1,164,932 |
| Payables | $634,761 | $2,925,059 | $2,870,122 | $1,164,932 |
| Accounts Payable | $634,761 | $2,925,059 | $2,870,122 | $1,162,850 |
| Equity | ||||
| Common Stock Equity | $3,968,222 | $-2,594,185 | $3,045,503 | $13,351,511 |
| Total Equity Gross Minority Interest | $3,968,222 | $-2,594,185 | $3,045,503 | $13,351,511 |
| Stockholders Equity | $3,968,222 | $-2,594,185 | $3,045,503 | $13,351,511 |
| Retained Earnings | $-58,535,261 | $-54,020,408 | $-44,072,662 | $-29,194,495 |
| Other Equity Interest | - | - | $-14,883,295 | $-14,883,295 |
| Preferred Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $778,732 | $76,444 | $71,807 | $70,727 |
| Share Issued | $778,732 | $76,444 | $71,807 | $70,727 |
| Tangible Book Value | $3,968,222 | $-2,594,185 | $3,045,503 | $13,351,511 |
| Invested Capital | $3,968,222 | $-2,293,471 | $3,045,503 | $13,351,511 |
| Working Capital | $3,542,616 | $-2,770,531 | $2,965,660 | $13,248,602 |
| Total Capitalization | $3,968,222 | $-2,594,185 | $3,045,503 | $13,351,511 |
| Additional Paid In Capital | $62,503,405 | $51,426,215 | $62,001,395 | $57,419,753 |
| Capital Stock | $78 | $8 | $65 | $9,548 |
| Common Stock | $78 | $8 | $65 | $9,548 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Net PPE | $425,606 | $176,346 | $79,843 | $102,909 |
| Treasury Shares Number | - | $0 | - | - |
| Dueto Related Parties Current | - | - | $0 | $2,082 |
Fetched: 2026-07-10
Cash Flow Statement (Annual)
| Metric | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-6,868,186 | $-8,417,236 | $-8,923,152 | $-6,720,448 |
| Operating Activities | ||||
| Operating Cash Flow | $-6,568,186 | $-8,269,993 | $-8,923,152 | $-6,613,990 |
| Cash Flow From Continuing Operating Activities | $-6,568,186 | $-8,269,993 | $-8,923,152 | $-6,613,990 |
| Operating Gains Losses | - | - | - | $-4,000 |
| Investing Activities | ||||
| Capital Expenditure | $-300,000 | $-147,243 | - | $-106,458 |
| Investing Cash Flow | $-300,000 | $-147,243 | $0 | $-106,458 |
| Cash Flow From Continuing Investing Activities | $-300,000 | $-147,243 | $0 | $-106,458 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $10,440,196 | $3,352,425 | $0 | $18,911,456 |
| Financing Cash Flow | $10,440,796 | $3,652,425 | $200 | $18,854,989 |
| Cash Flow From Continuing Financing Activities | $10,440,796 | $3,652,425 | $200 | $18,854,989 |
| Net Preferred Stock Issuance | $7,736,144 | $2,100,000 | $0 | - |
| Preferred Stock Issuance | $7,736,144 | $2,100,000 | $0 | - |
| Net Common Stock Issuance | $2,704,052 | $1,252,425 | $0 | $18,911,456 |
| Common Stock Issuance | $2,704,052 | $1,252,425 | $0 | $18,911,456 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Issuance Of Debt | $0 | $300,000 | $0 | $0 |
| End Cash Position | $3,948,658 | $376,048 | $5,140,859 | $14,063,811 |
| Beginning Cash Position | $376,048 | $5,140,859 | $14,063,811 | $1,929,270 |
| Changes In Cash | $3,572,610 | $-4,764,811 | $-8,922,952 | $12,134,541 |
| Proceeds From Stock Option Exercised | $600 | $0 | $200 | $2,200 |
| Net Issuance Payments Of Debt | $0 | $300,000 | $0 | $-58,667 |
| Net Short Term Debt Issuance | $0 | $300,000 | $0 | - |
| Short Term Debt Issuance | $0 | $300,000 | $0 | - |
| Net PPE Purchase And Sale | $-300,000 | $-147,243 | $0 | $-106,458 |
| Purchase Of PPE | $-300,000 | $-147,243 | $0 | $-106,458 |
| Change In Working Capital | $-2,438,467 | $670,666 | $2,349,324 | $1,327,181 |
| Change In Payables And Accrued Expense | $-2,288,942 | $54,937 | $1,707,272 | $693,584 |
| Change In Prepaid Assets | $-149,525 | $615,729 | $642,052 | $633,597 |
| Other Non Cash Items | $9,286 | $714 | - | $12,770 |
| Stock Based Compensation | $325,108 | $955,633 | $3,582,625 | $4,408,569 |
| Depreciation Amortization Depletion | $50,740 | $50,740 | $23,066 | $3,549 |
| Depreciation And Amortization | $50,740 | $50,740 | $23,066 | $3,549 |
| Depreciation | $50,740 | $50,740 | $23,066 | $3,549 |
| Net Income From Continuing Operations | $-4,514,853 | $-9,947,746 | $-14,878,167 | $-12,362,059 |
| Repayment Of Debt | - | - | $0 | $-58,667 |
| Net Long Term Debt Issuance | - | - | $0 | $-58,667 |
| Long Term Debt Payments | - | - | $0 | $-58,667 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-07-10